UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment

Oct 7 (Reuters) - Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country.